Cutibacterium namnetense is a rare type of anaerobic bacteria. Scientists first described it in 2016 after finding it in a bone infection. Since then, reports have shown that it causes a small number of human infections. These infections mostly involve implanted medical devices or surgical sites. A French study looked at 269 Cutibacterium samples collected from 2010 to 2012. It found C. namnetense comprised about 1.1% of the samples.
C.namnetense infections occur without any pattern. They don’t relate to specific locations or groups of people. The cases reported that bacteria can infect medical devices implanted in the body. C. namnetense responds well to many antibiotics like cephalosporins and tetracyclines. But some forms resist certain antibiotics like rifampin, metronidazole, or fusidic acid.
Cutibacterium namnetense is a pathogenic gram-positive bacterium. It belongs to the Actinomycetia class and Propionibacteriaceae family. It shows pleomorphism, it can change shape and size. Usually, it looks like a rod. Its width is 0.5 to 1.0 µm, and its length is between 1.0 to 4.0 µm.
Cutibacterium namnetense has a cell wall made of peptidoglycan. Teichoic and lipoteichoic acids are key parts strengthening the outer membrane. In adverse conditions, it can form endospores.
Cutibacterium namnetense has a genome size of 2.5 Mb. It has 2,222 protein-coding genes and 49 RNA genes. The bacterium shares 96.8% of its 16S rRNA gene sequence with C. acnes. It also shares 82.4% of its average nucleotide identity with C. acnes. C. namnetense has a gene that codes for hyaluronate lyase. This enzyme can break down hyaluronic acid. Hyaluronate lyase’s enzymatic activity is crucial for bacterial spread, tissue damage, and modulating the host immune response.
C.namnetense has two antigenic types, A and B. The types differ in whether they have a 10-kb plasmid carrying genes for fimbriae production. Type A strains have the plasmid and can produce fimbriae. But type B strains lack the plasmid and cannot produce fimbriae. This antigenic diversity could impact virulence and host interactions. The type strain of C. namnetense was isolated from a human bone infection in Nantes, France. It has the designations CCUG 66358, DSM 29427, and NTS 31307302. This strain serves as a reference for studying the unique features and pathogenicity of this bacterium.
The ways C. namnetense causes disease are not well understood. Its similarities with C. acnes suggest it may cause infections linked to foreign objects like implants, devices, or catheters. C. namnetense likely takes part in chronic inflammation and biofilm formation. It may make virulent enzymes like lipases, hyaluronidases, and proteases that break down host tissues, helping bacteria invade.
C.namnetense can spread through direct contact with contaminated skin or mucous membranes or through the bloodstream from other infected sites. Surgeries on the spine, heart, or liver may allow C. namnetense into the body.
Infections with C. namnetense differ based on location. It can cause bone infections like osteomyelitis and spondylodiscitis, heart valve infections (endocarditis), and abscesses in the chest, abdomen, prostate, or spleen. These trigger inflammation, tissue death, and scarring in affected areas. Additionally, C. namnetense infections may lead to widespread issues like blood infections, clots traveling through vessels, and infections in other organs.
Human defenses against the rare Cutibacterium namnetense still need exploration. Similar to other Cutibacterium species, the skin is the main barrier. It has physical and chemical defenses blocking external pathogens. The skin’s normal microbes also compete with potential pathogens, stopping their growth. C. namnetense is normally harmless skin flora. But it can cause infections if trauma, surgery, or implanted devices create openings.
The innate immune system is vital for recognizing and attacking C. namnetense. It uses pattern recognition receptors (PRRs) to detect components like lipoteichoic acids and peptidoglycan from the bacteria’s cell wall. These receptors include toll-like receptors (TLRs) and nucleotide-binding oligomerization domain (NOD) receptors on our cells. Detecting C. namnetense triggers the release of inflammatory molecules like cytokines and chemokines. These recruit and activate immune cells such as neutrophils, macrophages, and dendritic cells to engulf and destroy the bacteria.
The adaptive immune system adds another layer of defense, using B and T cells. B cells make antibodies targeting C. namnetense antigens. These antibodies help kill bacteria through opsonization, complement activation, or neutralization. Meanwhile, T cells secrete cytokines that regulate immune responses. They can also directly destroy infected cells. Specifically, CAMP factors from C. namnetense trigger B and T cell responses. It creates immunological memory, protecting against future Cutibacterium infections.
Cutibacterium namnetense can cause many kinds of infections in the body. It has been linked to infections in the spine after spine surgeries, showing it can affect the muscles and bones.
Cutibacterium namnetense has also caused infections of the heart valves, called infective endocarditis. This bacteria forms abscesses, which are pockets of infection. These abscesses from C. namnetense have been found in the chest, belly, prostate gland, and spleen. So, C. namnetense infections can be localized or occur throughout the body and organs.
To grow C. namnetense, blood or chocolate agar is utilized in anaerobic conditions. The growth time might stretch to two weeks so that it may be unidentified.
MALDI-TOF MS quickly identifies bacteria by analyzing protein patterns with mass spectrometry. While handy, C. namnetense and C. acnes have very similar spectra, making it challenging to differentiate them. For accuracy, set a high confidence threshold and confirm results via alternate tests.
Sequencing the gyrB gene, part of DNA gyrase, using PCR and DNA sequencing is the best way to identify C. namnetense. This method can distinguish it from C. acnes and other Cutibacterium species with high specificity.
The 16S rRNA gene sequencing approach uses PCR & DNA sequencing. Although it can differentiate C. namnetense, it may be less precise and sensitive than gyrB sequencing. The 16S rRNA gene is more identical across species and can vary within a species.
Before surgery, especially in body parts prone to C. namnetense like the neck and chest hygiene is crucial. Using antiseptics like iodine or chlorhexidine helps remove many microbes on the skin. It lowers the risk of C. namnetense entering the surgical area.
Stringent measures should be in place to prevent contamination of surgical instruments and implants with skin flora. Implementing practices to ensure aseptic conditions during surgery, including proper sterilization of instruments and maintaining a controlled environment, helps mitigate the risk of spreading C. namnetense.
In cases where C. namnetense infection is confirmed, a long course of antibiotics is necessary. Common antibiotics like amoxicillin, clindamycin, or levofloxacin have been successful treatments. Following the antibiotic regimen based on susceptibility testing results and the infection’s location and severity ensures effective treatment over the usual 3 to 6 month duration.
Cutibacterium namnetense is a rare type of anaerobic bacteria. Scientists first described it in 2016 after finding it in a bone infection. Since then, reports have shown that it causes a small number of human infections. These infections mostly involve implanted medical devices or surgical sites. A French study looked at 269 Cutibacterium samples collected from 2010 to 2012. It found C. namnetense comprised about 1.1% of the samples.
C.namnetense infections occur without any pattern. They don’t relate to specific locations or groups of people. The cases reported that bacteria can infect medical devices implanted in the body. C. namnetense responds well to many antibiotics like cephalosporins and tetracyclines. But some forms resist certain antibiotics like rifampin, metronidazole, or fusidic acid.
Cutibacterium namnetense is a pathogenic gram-positive bacterium. It belongs to the Actinomycetia class and Propionibacteriaceae family. It shows pleomorphism, it can change shape and size. Usually, it looks like a rod. Its width is 0.5 to 1.0 µm, and its length is between 1.0 to 4.0 µm.
Cutibacterium namnetense has a cell wall made of peptidoglycan. Teichoic and lipoteichoic acids are key parts strengthening the outer membrane. In adverse conditions, it can form endospores.
Cutibacterium namnetense has a genome size of 2.5 Mb. It has 2,222 protein-coding genes and 49 RNA genes. The bacterium shares 96.8% of its 16S rRNA gene sequence with C. acnes. It also shares 82.4% of its average nucleotide identity with C. acnes. C. namnetense has a gene that codes for hyaluronate lyase. This enzyme can break down hyaluronic acid. Hyaluronate lyase’s enzymatic activity is crucial for bacterial spread, tissue damage, and modulating the host immune response.
C.namnetense has two antigenic types, A and B. The types differ in whether they have a 10-kb plasmid carrying genes for fimbriae production. Type A strains have the plasmid and can produce fimbriae. But type B strains lack the plasmid and cannot produce fimbriae. This antigenic diversity could impact virulence and host interactions. The type strain of C. namnetense was isolated from a human bone infection in Nantes, France. It has the designations CCUG 66358, DSM 29427, and NTS 31307302. This strain serves as a reference for studying the unique features and pathogenicity of this bacterium.
The ways C. namnetense causes disease are not well understood. Its similarities with C. acnes suggest it may cause infections linked to foreign objects like implants, devices, or catheters. C. namnetense likely takes part in chronic inflammation and biofilm formation. It may make virulent enzymes like lipases, hyaluronidases, and proteases that break down host tissues, helping bacteria invade.
C.namnetense can spread through direct contact with contaminated skin or mucous membranes or through the bloodstream from other infected sites. Surgeries on the spine, heart, or liver may allow C. namnetense into the body.
Infections with C. namnetense differ based on location. It can cause bone infections like osteomyelitis and spondylodiscitis, heart valve infections (endocarditis), and abscesses in the chest, abdomen, prostate, or spleen. These trigger inflammation, tissue death, and scarring in affected areas. Additionally, C. namnetense infections may lead to widespread issues like blood infections, clots traveling through vessels, and infections in other organs.
Human defenses against the rare Cutibacterium namnetense still need exploration. Similar to other Cutibacterium species, the skin is the main barrier. It has physical and chemical defenses blocking external pathogens. The skin’s normal microbes also compete with potential pathogens, stopping their growth. C. namnetense is normally harmless skin flora. But it can cause infections if trauma, surgery, or implanted devices create openings.
The innate immune system is vital for recognizing and attacking C. namnetense. It uses pattern recognition receptors (PRRs) to detect components like lipoteichoic acids and peptidoglycan from the bacteria’s cell wall. These receptors include toll-like receptors (TLRs) and nucleotide-binding oligomerization domain (NOD) receptors on our cells. Detecting C. namnetense triggers the release of inflammatory molecules like cytokines and chemokines. These recruit and activate immune cells such as neutrophils, macrophages, and dendritic cells to engulf and destroy the bacteria.
The adaptive immune system adds another layer of defense, using B and T cells. B cells make antibodies targeting C. namnetense antigens. These antibodies help kill bacteria through opsonization, complement activation, or neutralization. Meanwhile, T cells secrete cytokines that regulate immune responses. They can also directly destroy infected cells. Specifically, CAMP factors from C. namnetense trigger B and T cell responses. It creates immunological memory, protecting against future Cutibacterium infections.
Cutibacterium namnetense can cause many kinds of infections in the body. It has been linked to infections in the spine after spine surgeries, showing it can affect the muscles and bones.
Cutibacterium namnetense has also caused infections of the heart valves, called infective endocarditis. This bacteria forms abscesses, which are pockets of infection. These abscesses from C. namnetense have been found in the chest, belly, prostate gland, and spleen. So, C. namnetense infections can be localized or occur throughout the body and organs.
To grow C. namnetense, blood or chocolate agar is utilized in anaerobic conditions. The growth time might stretch to two weeks so that it may be unidentified.
MALDI-TOF MS quickly identifies bacteria by analyzing protein patterns with mass spectrometry. While handy, C. namnetense and C. acnes have very similar spectra, making it challenging to differentiate them. For accuracy, set a high confidence threshold and confirm results via alternate tests.
Sequencing the gyrB gene, part of DNA gyrase, using PCR and DNA sequencing is the best way to identify C. namnetense. This method can distinguish it from C. acnes and other Cutibacterium species with high specificity.
The 16S rRNA gene sequencing approach uses PCR & DNA sequencing. Although it can differentiate C. namnetense, it may be less precise and sensitive than gyrB sequencing. The 16S rRNA gene is more identical across species and can vary within a species.
Before surgery, especially in body parts prone to C. namnetense like the neck and chest hygiene is crucial. Using antiseptics like iodine or chlorhexidine helps remove many microbes on the skin. It lowers the risk of C. namnetense entering the surgical area.
Stringent measures should be in place to prevent contamination of surgical instruments and implants with skin flora. Implementing practices to ensure aseptic conditions during surgery, including proper sterilization of instruments and maintaining a controlled environment, helps mitigate the risk of spreading C. namnetense.
In cases where C. namnetense infection is confirmed, a long course of antibiotics is necessary. Common antibiotics like amoxicillin, clindamycin, or levofloxacin have been successful treatments. Following the antibiotic regimen based on susceptibility testing results and the infection’s location and severity ensures effective treatment over the usual 3 to 6 month duration.
Cutibacterium namnetense is a rare type of anaerobic bacteria. Scientists first described it in 2016 after finding it in a bone infection. Since then, reports have shown that it causes a small number of human infections. These infections mostly involve implanted medical devices or surgical sites. A French study looked at 269 Cutibacterium samples collected from 2010 to 2012. It found C. namnetense comprised about 1.1% of the samples.
C.namnetense infections occur without any pattern. They don’t relate to specific locations or groups of people. The cases reported that bacteria can infect medical devices implanted in the body. C. namnetense responds well to many antibiotics like cephalosporins and tetracyclines. But some forms resist certain antibiotics like rifampin, metronidazole, or fusidic acid.
Cutibacterium namnetense is a pathogenic gram-positive bacterium. It belongs to the Actinomycetia class and Propionibacteriaceae family. It shows pleomorphism, it can change shape and size. Usually, it looks like a rod. Its width is 0.5 to 1.0 µm, and its length is between 1.0 to 4.0 µm.
Cutibacterium namnetense has a cell wall made of peptidoglycan. Teichoic and lipoteichoic acids are key parts strengthening the outer membrane. In adverse conditions, it can form endospores.
Cutibacterium namnetense has a genome size of 2.5 Mb. It has 2,222 protein-coding genes and 49 RNA genes. The bacterium shares 96.8% of its 16S rRNA gene sequence with C. acnes. It also shares 82.4% of its average nucleotide identity with C. acnes. C. namnetense has a gene that codes for hyaluronate lyase. This enzyme can break down hyaluronic acid. Hyaluronate lyase’s enzymatic activity is crucial for bacterial spread, tissue damage, and modulating the host immune response.
C.namnetense has two antigenic types, A and B. The types differ in whether they have a 10-kb plasmid carrying genes for fimbriae production. Type A strains have the plasmid and can produce fimbriae. But type B strains lack the plasmid and cannot produce fimbriae. This antigenic diversity could impact virulence and host interactions. The type strain of C. namnetense was isolated from a human bone infection in Nantes, France. It has the designations CCUG 66358, DSM 29427, and NTS 31307302. This strain serves as a reference for studying the unique features and pathogenicity of this bacterium.
The ways C. namnetense causes disease are not well understood. Its similarities with C. acnes suggest it may cause infections linked to foreign objects like implants, devices, or catheters. C. namnetense likely takes part in chronic inflammation and biofilm formation. It may make virulent enzymes like lipases, hyaluronidases, and proteases that break down host tissues, helping bacteria invade.
C.namnetense can spread through direct contact with contaminated skin or mucous membranes or through the bloodstream from other infected sites. Surgeries on the spine, heart, or liver may allow C. namnetense into the body.
Infections with C. namnetense differ based on location. It can cause bone infections like osteomyelitis and spondylodiscitis, heart valve infections (endocarditis), and abscesses in the chest, abdomen, prostate, or spleen. These trigger inflammation, tissue death, and scarring in affected areas. Additionally, C. namnetense infections may lead to widespread issues like blood infections, clots traveling through vessels, and infections in other organs.
Human defenses against the rare Cutibacterium namnetense still need exploration. Similar to other Cutibacterium species, the skin is the main barrier. It has physical and chemical defenses blocking external pathogens. The skin’s normal microbes also compete with potential pathogens, stopping their growth. C. namnetense is normally harmless skin flora. But it can cause infections if trauma, surgery, or implanted devices create openings.
The innate immune system is vital for recognizing and attacking C. namnetense. It uses pattern recognition receptors (PRRs) to detect components like lipoteichoic acids and peptidoglycan from the bacteria’s cell wall. These receptors include toll-like receptors (TLRs) and nucleotide-binding oligomerization domain (NOD) receptors on our cells. Detecting C. namnetense triggers the release of inflammatory molecules like cytokines and chemokines. These recruit and activate immune cells such as neutrophils, macrophages, and dendritic cells to engulf and destroy the bacteria.
The adaptive immune system adds another layer of defense, using B and T cells. B cells make antibodies targeting C. namnetense antigens. These antibodies help kill bacteria through opsonization, complement activation, or neutralization. Meanwhile, T cells secrete cytokines that regulate immune responses. They can also directly destroy infected cells. Specifically, CAMP factors from C. namnetense trigger B and T cell responses. It creates immunological memory, protecting against future Cutibacterium infections.
Cutibacterium namnetense can cause many kinds of infections in the body. It has been linked to infections in the spine after spine surgeries, showing it can affect the muscles and bones.
Cutibacterium namnetense has also caused infections of the heart valves, called infective endocarditis. This bacteria forms abscesses, which are pockets of infection. These abscesses from C. namnetense have been found in the chest, belly, prostate gland, and spleen. So, C. namnetense infections can be localized or occur throughout the body and organs.
To grow C. namnetense, blood or chocolate agar is utilized in anaerobic conditions. The growth time might stretch to two weeks so that it may be unidentified.
MALDI-TOF MS quickly identifies bacteria by analyzing protein patterns with mass spectrometry. While handy, C. namnetense and C. acnes have very similar spectra, making it challenging to differentiate them. For accuracy, set a high confidence threshold and confirm results via alternate tests.
Sequencing the gyrB gene, part of DNA gyrase, using PCR and DNA sequencing is the best way to identify C. namnetense. This method can distinguish it from C. acnes and other Cutibacterium species with high specificity.
The 16S rRNA gene sequencing approach uses PCR & DNA sequencing. Although it can differentiate C. namnetense, it may be less precise and sensitive than gyrB sequencing. The 16S rRNA gene is more identical across species and can vary within a species.
Before surgery, especially in body parts prone to C. namnetense like the neck and chest hygiene is crucial. Using antiseptics like iodine or chlorhexidine helps remove many microbes on the skin. It lowers the risk of C. namnetense entering the surgical area.
Stringent measures should be in place to prevent contamination of surgical instruments and implants with skin flora. Implementing practices to ensure aseptic conditions during surgery, including proper sterilization of instruments and maintaining a controlled environment, helps mitigate the risk of spreading C. namnetense.
In cases where C. namnetense infection is confirmed, a long course of antibiotics is necessary. Common antibiotics like amoxicillin, clindamycin, or levofloxacin have been successful treatments. Following the antibiotic regimen based on susceptibility testing results and the infection’s location and severity ensures effective treatment over the usual 3 to 6 month duration.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
